NCT07200375View on ClinicalTrials.gov

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

July 31, 2030

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Glofitamab

Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY